Cidara Therapeutics To Present Data On Novel Antifungal CD101 At The Global Joint Conference Of ICHS And INFOCUS

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for invasive fungal infections will be presented at the joint conference of the International Immunocompromised Host Society (ICHS) and INFOCUS Latinomérica from November 13-15, 2016 in Santiago, Chile. CD101 is Cidara's lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class.

The ICHS and INFOCUS are prestigious annual events highlighting the latest developments related to infections in immunocompromised patients and fungal infections, respectively. They are hosting their meetings together for the first time to address the increasing incidence of fungal infections in immunocompromised patients.

CD101 data being presented at the joint ICHS/INFOCUS conference will include new results from preclinical studies evaluating subcutaneous administration of the compound, which represents a novel approach in antifungal treatment and prevention. This abstract was selected by the conference's Scientific Committee as one of the top works of all that were submitted, a recognition that reflects the importance of and interest in this research. A second presentation will review data from two recently completed Phase 1 dose-escalation trials of CD101 IV that demonstrate the compound's clinical pharmacokinetics, safety and tolerability. CD101 IV is currently being developed as a once-weekly treatment for invasive fungal infections.

"Cidara's presence at this international forum demonstrates our commitment to broadening the dissemination of our scientific work in novel antifungal drug development and advancing new treatment options to support immunocompromised patients, who are at high risk of developing life-threatening fungal infections," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We look forward to engaging with this scientific community to share the latest results of our CD101 clinical research, including the exciting study investigating the potential to broaden utility for CD101 through availability of a subcutaneous injection."

If you liked this article you might like

IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up